ALX Oncology Holdings Inc is a clinical-stage immuno-oncology company focused on helping patients fight cancer by developing a pipeline of product candidates based on expertise in protein engineering and oncology led by the CD47 blocker, evorpacept, currently in phase 1 and 2 clinical trials. Cancer cells leverage CD47, a cell surface protein, as a don't eat me signal to evade detection by the immune system. The company is developing a next-generation checkpoint inhibitor designed to have a high affinity for CD47 and to avoid the limitations caused by hematologic toxicities inherent in other CD47 blocking approaches.

NASDAQ:ALXO

ALX Oncology Holdings Inc.

Last Close

16.62

03/05 20:00

Market Cap

775.66M

Beta: 1.66

Volume Today

447K

Avg: 271.68K

PE Ratio

−4.46

PFCF: −6.91

locale

market

industry

website

crunchbase

ipo date

Earnings

Earnings per Share (Estimate*)

Revenue (Estimate*)

Metrics